Cancer Vaccine

GM-CSF bound to membrane increases efficacy of vaccine against melanoma

Published in Vaccine Weekly, December 25th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - A therapeutic vaccine consisting of cells that produce a membrane-bound form of granulocyte-macrophage colony-stimulating factor (mbGM-CSF) was more effective against melanoma tumors in humans than were vaccines containing cells that secreted GM-CSF.

"The intent was to enhance antigen presentation by increasing interactions between the tumor cell lines in the vaccine and GM-CSF receptor positive antigen presenting cells, notably the patient's Langerhans cells residing within the intradermal injection site," explained S. Yei and colleagues at Immune Response Corporation in Carlsbad, California.

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry